CYTK : Summary for Cytokinetics, Incorporated - Yahoo Finance

U.S. Markets open in 5 hrs 18 mins

Cytokinetics, Incorporated (CYTK)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.82+0.62 (+6.13%)
At close: 4:00PM EST
People also watch
CORTGTXIARRYCYCCCRIS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close10.20
Open10.20
Bid9.85 x 600
Ask0.00 x
Day's Range10.20 - 10.90
52 Week Range6.00 - 13.45
Volume218,590
Avg. Volume301,824
Market Cap449.14M
Beta2.35
PE Ratio (TTM)27.76
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire12 hours ago

    Cytokinetics to Present at March Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017-- Cytokinetics, Inc. announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following investor ...

  • Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017
    Capital Cube5 days ago

    Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017

    Categories: Yahoo Finance Get free summary analysis Cytokinetics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Cytokinetics, Inc. – Acorda Therapeutics, Inc., Amgen Inc. and Array BioPharma Inc. (ACOR-US, AMGN-US and ARRY-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
    Zacks8 days ago

    ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y

    ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.